Johnson & Johnson has agreed to acquire Ollin Biosciences, a clinical-stage biotech focused on therapies for serious eye diseases. Quartz and the Wall Street Journal Tech both report a purchase value of $2.2 billion, with the deal structure described by Quartz as including $750 million funded by Blackstone Life Sciences for Phase 3 development of the lead drug candidate, OLN324.
Other outlets frame the same potential acquisition as larger. Seeking Alpha and Investing.com both cite reports that place the figure at up to $3.4 billion, referencing discussions or reporting attributed to the Financial Times. The Financial Times likewise describes Johnson & Johnson looking to buy the company for up to $3.4bn and situates the news within a wider stretch of biotechnology deal-making.
Overall, the sources align on the target company (Ollin Biosciences) and its eye-disease focus, but they differ on the reported headline price and on how much detail is provided about deal funding and drug-stage context.